ACADEMIA

8-Week Treatment with Maviret a Promising First-Line Option for Hepatitis C: Hepatologist

January 11, 2019
Hiromitsu Kumada, a hepatologist at Toranomon Hospital, said that treatment with the hepatitis C drug Maviret (glecaprevir + pibrentasvir) at his hospital has produced the same results as Maviret’s Japan PIII study. “We’ve gone beyond the age of 12-week treatment…

To read the full story

ACADEMIA

By Shinya Sato

As 2019 rolls in, we expect to see a flurry of approvals in the Japanese regenerative medicine arena, with regulatory decisions anticipated by the end of the year for Novartis Pharma’s CAR-T therapy and many more products, which could bring…

Takeda Pharmaceutical completed the £46 billion acquisition of Shire on January 8, vaulting itself into the top 10 league of…

By Gregory Ng

To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…

By Reiji Anasako

While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…